Details of Disease

General Information of Disease (ID: DISVGJET)

• Disease Name: Neuroendocrine cancer
• Synonyms: neuroendocrine carcinoma; neuroendocrine cancer; NEC
• Disease Class: 2B72: Stomach cancer
• Definition: A malignant neuroendocrine neoplasm composed of cells containing secretory granules that stain positive for NSE and chromogranin. The neoplastic cells are often round and form clusters or trabecular sheets. Representative examples are small cell carcinoma, large cell neuroendocrine carcinoma, and Merkel cell carcinoma.
• Disease Hierarchy:
  DISH9F1N: Carcinoma
  DISNPLOO: Neuroendocrine neoplasm
  DISKTBM1: Malignant endocrine neoplasm
  DISVGJET: Neuroendocrine cancer
• ICD Code:
  ICD-11: ICD-11: 2B72.1
  ICD-9: ICD-9: 209
  Expand ICD-11: '2D4Y
  Expand ICD-9: 209
• Disease Identifiers:
  MONDO ID: MONDO_0002120
  MESH ID: D018278
  UMLS CUI: C0206695
  MedGen ID: 104919
  SNOMED CT ID: 253000007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ga 68 dotatate	DMFIIDD	Approved	NA	[1]
Iobenguane I-123	DM80OEZ	Approved	Small molecular drug	[2]
Lutetium Lu 177 dotatate	DMN1XVC	Approved	NA	[3]
Octreotide	DMHIDCJ	Approved	Small molecular drug	[4]
Retifanlimab	DMRKTCP	Approved	Antibody	[5]

This Disease is Treated as An Indication in 23 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
177-Lu-edotreotide	DMFSHI6	Phase 3	Somatostatin analogue	[6]
177-Lu-oxodotreotide	DMMZS2T	Phase 3	Small molecular drug	[7]
177Lu-DOTA-octreotate	DMP5L8S	Phase 3	NA	[8]
PDR001	DM53J6B	Phase 3	Antibody	[9]
PV-10	DM95UYC	Phase 3	Small molecular drug	[10]
Rova-T	DMNGCAD	Phase 3	NA	[10]
RRx-001	DMQM2FH	Phase 3	Small molecular drug	[10]
Selinexor	DMBD4K3	Phase 3	Small molecular drug	[10]
Sulfatinib	DMPOTM4	Phase 3	NA	[11]
166Ho microspheres	DME6VDB	Phase 2	Radiopharmaceutical therapy agent	[12]
CA4P	DM9R0ZL	Phase 2	NA	[8]
CVM-1118	DMP86RS	Phase 2	Small molecular drug	[13]
Metaiodobenzylguanidine I-131	DMNST69	Phase 2	Small molecular drug	[8]
ONC201	DMM5SCF	Phase 2	NA	[10]
SomaKit-TOC; gallium (68Ga) edotreotide	DMDHON7	Phase 2	NA	[8]
177Lu-labelled DOTA-JR11	DMVZ9XL	Phase 1/2	Radiopharmaceutical therapy agent	[14]
PEN-221	DMMAUOK	Phase 1/2	NA	[10]
SNX-5422	DMIU0VP	Phase 1/2	Small molecular drug	[10]
212Pb-labelled DOTAMTATE	DMN9MPX	Phase 1	Radiopharmaceutical therapy agent	[15]
AlphaMedix	DMBVM1Q	Phase 1	Peptide	[15]
AMG 757	DMLYP2N	Phase 1	Antibody	[16]
DP-1038	DMKLCLO	Phase 1	NA	[10]
XmAb18087	DMB3C0Q	Phase 1	NA	[10]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
98mTc-CIM-ANT	DMJ1VAE	Investigative	NA	[17]
99mTc-MIP-1407	DMYPD5L	Investigative	NA	[18]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 19 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ARF1	TT70KXY	Limited	Biomarker	[19]
PAX5	TTA4REJ	Limited	Biomarker	[20]
DPEP1	TTYUENF	moderate	Biomarker	[21]
GLRX	TTRJCNG	moderate	Biomarker	[22]
GM2A	TTGOFW6	moderate	Genetic Variation	[23]
GRIA2	TTWM461	moderate	Altered Expression	[24]
LY96	TT8S9AV	moderate	Genetic Variation	[23]
PCSK2	TT46F0P	moderate	Biomarker	[25]
RHBDF2	TTH1ZOP	moderate	Biomarker	[26]
SQLE	TTE14XG	moderate	Biomarker	[27]
CD79B	TTBN5I7	Strong	Genetic Variation	[28]
CDKN1B	TTLGFVW	Strong	Altered Expression	[29]
DLL3	TT1C9K6	Strong	Biomarker	[30]
PGRMC1	TTY3LAZ	Strong	Biomarker	[31]
SST	TTWF7UG	Strong	Biomarker	[32]
CD274	TT8ZLTI	Definitive	Biomarker	[33]
ELK3	TT5OJMV	Definitive	Altered Expression	[34]
EPHB1	TT8MDAC	Definitive	Altered Expression	[34]
SLC6A2	TTAWNKZ	Definitive	Altered Expression	[34]

This Disease Is Related to 23 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CHGA	OTXYX5JH	Limited	Biomarker	[35]
TTF1	OT4K90WD	Limited	Biomarker	[36]
DPT	OTINRFC7	moderate	Biomarker	[37]
DSC2	OTODVH8K	moderate	Genetic Variation	[38]
DSC3	OTYG47F8	moderate	Genetic Variation	[38]
INSM1	OTG8RV8E	moderate	Biomarker	[39]
ISL1	OTVNVKAX	moderate	Biomarker	[40]
NAPSA	OT6F8IAL	moderate	Altered Expression	[38]
NEUROD1	OTZQ7QJ2	moderate	Altered Expression	[41]
NKX2-3	OTF4IL5J	moderate	Altered Expression	[24]
OTP	OTS0JN6Y	moderate	Altered Expression	[42]
PPP1R12A	OT4AVU95	moderate	Biomarker	[43]
TEAD2	OTM8YMYT	moderate	Altered Expression	[44]
TMPRSS11A	OTB35677	moderate	Biomarker	[45]
TRAM1	OT3I0H8E	moderate	Biomarker	[37]
FA2H	OT8HA13U	Strong	Altered Expression	[46]
IGF2BP3	OTB97VIK	Strong	Altered Expression	[47]
MEN1	OTN6U6V0	Strong	Biomarker	[31]
NKX2-1	OTCMEJTA	Strong	Biomarker	[36]
NUTM1	OTONYC08	Strong	Biomarker	[48]
OR51E1	OTB7Q65H	Strong	Biomarker	[49]
RNASET2	OTWY64L7	Strong	Biomarker	[50]
SOX11	OT4LG7LA	Strong	Altered Expression	[51]

References

• [1] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [2] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Octreotide FDA Label
• [5] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761334.
• [6] ClinicalTrials.gov (NCT04919226) A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin. U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT01842165) 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (LUMEN). U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] ClinicalTrials.gov (NCT02589821) Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT02067988) Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study (HEPAR_Plus). U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT03600233) Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT02592707) Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs. U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT03466216) Phase 1 Study of AlphaMedix in Adult Subjects With SSTR (+) NET. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT04702737) A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer. U.S. National Institutes of Health.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359).
• [19] IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells.J Cell Mol Med. 2015 May;19(5):948-59. doi: 10.1111/jcmm.12473. Epub 2015 Mar 8.
• [20] Novel Finding of Paired Box 5 (PAX5) Cytoplasmic Staining in Well-differentiated Rectal Neuroendocrine Tumors (Carcinoids) and Its Diagnostic and Potentially Prognostic Utility.Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):454-460. doi: 10.1097/PAI.0000000000000635.
• [21] 99mTc-MDP Uptake in Diffuse Pleural Recurrences of Pulmonary Neuroendocrine Carcinoma.Clin Nucl Med. 2017 Feb;42(2):133-134. doi: 10.1097/RLU.0000000000001473.
• [22] Contribution of glutaredoxin-1 to S-glutathionylation of endothelial nitric oxide synthase for mesenteric nitric oxide generation in experimental necrotizing enterocolitis.Transl Res. 2017 Oct;188:92-105. doi: 10.1016/j.trsl.2016.01.004. Epub 2016 Jan 18.
• [23] Association of neonatal necrotizing enterocolitis with myeloid differentiation-2 and GM2 activator protein genetic polymorphisms.Mol Med Rep. 2015 Jul;12(1):974-80. doi: 10.3892/mmr.2015.3499. Epub 2015 Mar 17.
• [24] Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas.Mod Pathol. 2009 Feb;22(2):261-72. doi: 10.1038/modpathol.2008.174. Epub 2008 Oct 24.
• [25] Does neutrophil/lymphocyte ratio have good diagnostic value in neonatal necrotizing colitis?.J Matern Fetal Neonatal Med. 2019 Sep;32(18):3026-3033. doi: 10.1080/14767058.2018.1455182. Epub 2018 Mar 27.
• [26] Clinical value of (99m)Tc-HYNIC-TOC SPECT/CT for the diagnosis primary small cell neuroendocrine carcinomas of the nasal cavity and paranasal sinuses.Clin Imaging. 2018 Nov-Dec;52:365-369. doi: 10.1016/j.clinimag.2018.09.010. Epub 2018 Sep 20.
• [27] A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition.Nat Commun. 2019 Jan 9;10(1):96. doi: 10.1038/s41467-018-07959-4.
• [28] Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.Am J Surg Pathol. 2020 Apr;44(4):444-455. doi: 10.1097/PAS.0000000000001386.
• [29] Expression of p21Cip1/Waf1 and p27Kip1 in small cell neuroendocrine carcinoma of the uterine cervix.Int J Surg Pathol. 2008 Jan;16(1):11-5. doi: 10.1177/1066896907309574.
• [30] Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy.Cancer Sci. 2019 Oct;110(10):3122-3131. doi: 10.1111/cas.14157. Epub 2019 Aug 14.
• [31] Two well-differentiated pancreatic neuroendocrine tumor mouse models.Cell Death Differ. 2020 Jan;27(1):269-283. doi: 10.1038/s41418-019-0355-0. Epub 2019 Jun 3.
• [32] Management of Small Bowel Neuroendocrine Tumors.Cancers (Basel). 2019 Sep 18;11(9):1395. doi: 10.3390/cancers11091395.
• [33] Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.Clin Genitourin Cancer. 2019 Apr;17(2):145-153.e5. doi: 10.1016/j.clgc.2018.12.007. Epub 2018 Dec 21.
• [34] APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):599-605. doi: 10.1097/PAI.0000000000000695.
• [35] A case of mixed adenoneuroendocrine carcinoma of the pancreas: Immunohistochemical analysis for histogenesis.Medicine (Baltimore). 2017 Mar;96(9):e6225. doi: 10.1097/MD.0000000000006225.
• [36] Differentiating Merkel cell carcinoma of lymph nodes without a detectable primary skin tumor from other metastatic neuroendocrine carcinomas: The ELECTHIP criteria.J Am Acad Dermatol. 2018 May;78(5):964-972.e3. doi: 10.1016/j.jaad.2017.11.037. Epub 2017 Nov 24.
• [37] The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma.Mol Cancer Res. 2015 Feb;13(2):339-47. doi: 10.1158/1541-7786.MCR-14-0262. Epub 2014 Oct 8.
• [38] Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas.Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):292-7. doi: 10.1097/PAI.0b013e31826fd4f3.
• [39] Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):237-242. doi: 10.1097/PAI.0000000000000715.
• [40] The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.Ann Diagn Pathol. 2018 Dec;37:30-34. doi: 10.1016/j.anndiagpath.2018.09.005. Epub 2018 Sep 13.
• [41] The expression of NeuroD and mASH1 in the gastroenteropancreatic neuroendocrine tumors.Mod Pathol. 2008 Nov;21(11):1363-70. doi: 10.1038/modpathol.2008.121. Epub 2008 Jun 27.
• [42] Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.Endocr Pathol. 2019 Mar;30(1):35-42. doi: 10.1007/s12022-018-9559-y.
• [43] A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma.Hum Pathol. 2019 Jun;88:48-59. doi: 10.1016/j.humpath.2019.03.007. Epub 2019 Apr 1.
• [44] SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString).Future Oncol. 2015;11(7):1027-36. doi: 10.2217/fon.15.18.
• [45] ECRG1, a novel esophageal gene, cloned and identified from human esophagus and its inhibition effect on tumors.Carcinogenesis. 2008 Jan;29(1):157-60. doi: 10.1093/carcin/bgm203. Epub 2007 Oct 29.
• [46] High FA2H and UGT8 transcript levels predict hydroxylated hexosylceramide accumulation in lung adenocarcinoma.J Lipid Res. 2019 Oct;60(10):1776-1786. doi: 10.1194/jlr.M093955. Epub 2019 Aug 13.
• [47] Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer similar to other high-grade neuroendocrine carcinomas.Hum Pathol. 2009 Feb;40(2):238-43. doi: 10.1016/j.humpath.2008.07.009. Epub 2008 Oct 5.
• [48] Cytologic findings of NUT midline carcinoma in the hilum of the lung.Diagn Cytopathol. 2015 Sep;43(9):739-42. doi: 10.1002/dc.23291. Epub 2015 Jul 3.
• [49] Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas.Eur J Endocrinol. 2013 Jan 17;168(2):253-61. doi: 10.1530/EJE-12-0814. Print 2013 Feb.
• [50] New insights into hypoxia-related mechanisms involved in different microvascular patterns of bronchopulmonary carcinoids and poorly differentiated neuroendocrine carcinomas. Role of ribonuclease T2 (RNASET2) and HIF-1.Hum Pathol. 2018 Sep;79:66-76. doi: 10.1016/j.humpath.2018.04.028. Epub 2018 May 12.
• [51] SOX11: a potentially useful marker in surgical pathology: a systematic analysis of SOX11 expression in epithelial and non-epithelial tumours.Histopathology. 2019 Feb;74(3):391-405. doi: 10.1111/his.13757. Epub 2018 Dec 2.